NCT02678533 (FancoMob) is a Phase 1, PHASE2 clinical trial of G-CSF in Fanconi Anemia, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT02678533?

NCT02678533 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02678533?

Interventions in NCT02678533: G-CSF, Plerixafor.

What condition does NCT02678533 study?

NCT02678533 studies Fanconi Anemia.

Is NCT02678533 still recruiting?

NCT02678533 is currently completed. Last updated 11 September 2025.

Last reviewed 2025-09-11 · How we verify

NCT02678533: FancoMob

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor

Completed Phase 1, PHASE2 Last updated 11 September 2025

What this trial tests

Phase 1, PHASE2 trial testing G-CSF in Fanconi Anemia in 4 participants. Completed in 3 May 2019.

Timeline

10 February 2017

Primary endpoint
20 November 2018

3 May 2019

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	10 February 2017
Primary completion	20 November 2018
Estimated completion	3 May 2019
Sites	1 location across France

Drugs / interventions tested

G-CSF (g-csf) — full drug profile →
Plerixafor (plerixafor) — full drug profile →

Conditions studied

Fanconi Anemia — all drugs for Fanconi Anemia →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 2 to 17, any sex, with Fanconi Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the feasibility of Plerixafor used in combination with G-CSF (Granulocyte Colony Stimulating Factor) in 5 Fanconi anemia patients to mobilize and collect a sufficient number of peripheral blood CD34+ cells for peripheral blood apheresis, for further gene therapy study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.
Cambier S, Gouwy M, Proost P. · · 2023 · cited 387× · PMID 36725964 · DOI 10.1038/s41423-023-00974-6

Verify or expand the search:

Other trials of G-CSF

Trials testing the same drug.

NCT07428486 — A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractor · Phase 1 · not yet recruiting
NCT07441967 — The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Bu · Phase 2 · not yet recruiting
NCT04370795 — Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-bas · Phase 1, PHASE2 · withdrawn
NCT07002827 — Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standar · NA · not yet recruiting
NCT06547112 — A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Moti · Phase 1 · completed

Other recruiting trials for Fanconi Anemia

Currently open trials in the same condition.

NCT06744283 — Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia · recruiting
NCT05687149 — Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia · recruiting
NCT05973656 — Role of Acetaldehyde in the Development of Oral Cancer · NA · recruiting
NCT04437771 — Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy · active not recruiting
NCT04232085 — Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failu · Phase 2 · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02678533 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 11 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02678533.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing